An exploratory analysis of clinical and sociodemographic factors in CGRP-induced migraine attacks: A REFORM study

Cephalalgia. 2023 Oct;43(10):3331024231206375. doi: 10.1177/03331024231206375.

Abstract

Objective: To investigate whether clinical and sociodemographic factors are associated with calcitonin gene-related peptide (CGRP) induced migraine attacks.

Methods: A total of 139 participants with migraine received a 20-minute intravenous infusion of CGRP (1.5 µg/min) on a single experiment day. The incidence of CGRP-induced migraine attacks was recorded using a headache diary during the 12-hour observational period post-infusion. Univariable and multivariable regression analyses were conducted to examine potential predictors' relationship with CGRP-induced migraine attacks.

Results: CGRP-induced migraine attacks were reported in 110 (79%) of 139 participants. Univariable analysis revealed that participants with cutaneous allodynia had higher odds of developing CGRP-induced migraine attacks, compared with those without allodynia (OR, 2.97, 95% CI, 1.28 to 7.43). The subsequent multivariable analysis confirmed this association (OR, 3.26, 95% CI, 1.32 to 8.69) and also found that participants with migraine with aura had lower odds of developing CGRP-induced migraine attacks (OR, 0.32, 95% CI, 0.12 to 0.84).

Conclusion: Our results suggest that cutaneous allodynia and aura play a role in CGRP-induced migraine attacks, while other clinical and sociodemographic factors do not seem to have any noticeable impact. This indicates that the CGRP provocation model is robust, as the CGRP hypersensitivity remained unaffected despite differences among a heterogeneous migraine population.Trial Registration: ClinicalTrials.gov Identifier: NCT04592952.

Keywords: CGRP hypersensitivity; Headache disorders; prediction.

MeSH terms

  • Calcitonin Gene-Related Peptide* / adverse effects
  • Calcitonin Gene-Related Peptide* / pharmacology
  • Headache
  • Humans
  • Hyperalgesia / chemically induced
  • Hyperalgesia / epidemiology
  • Migraine Disorders* / chemically induced
  • Migraine Disorders* / drug therapy
  • Migraine Disorders* / epidemiology
  • Sociodemographic Factors

Substances

  • Calcitonin Gene-Related Peptide

Associated data

  • ClinicalTrials.gov/NCT04592952